What is the Impact Factor of Therapeutic Advances in Respiratory Disease?

According to the latest Clarivate Journal Citation Reports (JCR), the Journal Impact Factor of Therapeutic Advances in Respiratory Disease is 3.20, ranking in quartile Q2 of Web of Science (SCIE).

Is Therapeutic Advances in Respiratory Disease indexed in Web of Science or Scopus?

Yes, Therapeutic Advances in Respiratory Disease is indexed in Web of Science (SCIE, Q2 quartile). Furthermore, in Scopus (SCImago), it holds an SJR rating of 1.009 (Q1) and an H-index of 59.

Who publishes Therapeutic Advances in Respiratory Disease and what is the Article Processing Charge (APC)?

Therapeutic Advances in Respiratory Disease is published by SAGE Publications Ltd. The estimated Article Processing Charge (APC) is approximately $3,385 USD, subject to institutional waivers and corresponding author affiliations.

What is the ISO-4 abbreviation and acronym of Therapeutic Advances in Respiratory Disease?

The official ISO-4 abbreviation of Therapeutic Advances in Respiratory Disease is "THER ADV RESPIR DIS". This standardized title abbreviation is used in citation lists conforming to IEEE, APA, Harvard, or Vancouver styles.

WoS SCIE Q2Scopus Q1SCImago #4,845Gold OA

Therapeutic Advances in Respiratory Disease

Abbreviation (ISO):THER ADV RESPIR DIS

•

Identifier (ISSN):1753-4658(Print)/1753-4666(Online)

•

Publisher:SAGE Publications Ltd

Official Website Submission Portal Compare

Clarivate IF (2026)

3.2↑ +0.2

Journal Impact Factor

IF Trend↓

WoS Quartile

WoS SCIEJCR Quartile

Clarivate WoS JCR

WoS Categories↓

JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Therapeutic Advances in Respiratory Disease

WoS Q2

Annual Impact Factor Metric

Current (2026):3.2

Scopus SJR & RankScopus Q1

1.009

#4,845

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025

H-Index (2025)

59 papers with at least that number of citations each

WoS: SCIE / JCRQ2

Self-Citation Rate3%

Safe Level (< 15%)Warning Level (> 20%)

Self-citation below 15% indicates strong scholarly independence.

Volume & Open AccessGold OA

48articles/year

100% Gold OA•73.85% Original Research

Aims & Scope

Therapeutic Advances in Respiratory Disease delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of respiratory disease.

Topics Covered (Recognized by AI)

MedicineInternal MedicineBiologyPathologyPsychologySurgeryPsychiatryImmunologyGeneticsIntensive Care MedicineAnesthesiologyPhilosophyChemistryLinguisticsBiochemistryRadiologyMathematicsAnatomyEndocrinologyStatisticsPhysicsPharmacology

Primary Research Areas

Respiratory System

Official Website NLM PubMed Catalog Submission Portal SCImago Profile

0 calls

Special Issues

Calls for Papers

No active Calls for Papers found for this journal.

Expand

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI

JCRSCIE2026

RESPIRATORY SYSTEM

Rank43/107

IndexSCIE

JCISCIE2026

RESPIRATORY SYSTEM

Rank38/107

IndexSCIE

Category	Index	Rank	Quartile
RESPIRATORY SYSTEM	JCRSCIE	43/107	Q2
RESPIRATORY SYSTEM	JCISCIE	38/107	Q2

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year

2026Latest

IF3.2

Articles / Year59

Total Citations9

2025

IF3

Articles / Year105

Total Citations367

2024

IF3.3

Articles / Year95

Total Citations503

2023

IF4.3

Articles / Year79

Total Citations806

2022

IF5.158

Articles / Year67

Total Citations1,189

Year	Impact Factor	Articles / Year	Total Citations
2026	3.2	59	9
2025	3	105	367
2024	3.3	95	503
2023	4.3	79	806
2022	5.158	67	1,189
2021	4.031	49	1,074
2020	3.095	95	2,664
2019	3.286	61	1,680
2018	3.592	39	1,938
2017	—	26	869
2016	—	51	1,662
2015	—	42	1,532

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #4,845Scopus Q1SCImago Profile

Scopus Coverage:2007-2026

•

Scopus Broad Areas:Medicine

Scopus Citation Rank (SJR)Q1

1.009

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q1

Citations / Doc (2 years)

3.19

Average citations received per document published in the 2-year window.

2-Year Citation Window

Estimated Publication Fee (APC)

$3,385 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations859

3-Year Documents239

Citable Documents236

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate46.9%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

Pharmacology (medical)Q1

Pulmonary and Respiratory MedicineQ1

Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth

Self-citation: 3%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):

3区 (Zone 3)Medicine

Minor Category (Specific Field):

3区RESPIRATORY SYSTEM

CAS Early Warning List History:

Updated annually: 2020 – 2024

2020

Not warned

2021

Not warned

2022

Not warned

2023

Not warned

2024

Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Therapeutic Advances in Respiratory Disease (abbr: THER ADV RESPIR DIS, ISSN: 1753-4658) is a peer-reviewed international scholarly journal in the field of RESPIRATORY SYSTEM, published by SAGE Publications Ltd in England. The periodical holds a Journal Impact Factor (JIF) of 3.20, ranking in quartile Q2 of Web of Science (SCIE), a Scopus SJR indicator of 1.009 (Q1), an H-index of 59.

The journal enforces rigorous peer evaluation with an annual output of approximately 48 scientific articles. In terms of accessibility and author fees, it operates under the Gold OA model with an estimated APC of $3,385 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.